Loargys® (pegzilarginase) granted marketing authorization in Oman for the treatment of arginase 1 deficiency (ARG1-D)

Immedica announced on Dec. 10, 2025 that Loargys (pegzilarginase), the first and only disease‑modifying therapy for arginase 1 deficiency (ARG1‑D), has received marketing authorization in Oman for patients aged 2 and older — the company’s first approval in the MENA region and an extension of prior EU and UK approvals. The clearance enables Immedica to commercialize a treatment that rapidly reduces plasma arginine and toxic metabolites for a rare urea‑cycle disorder with high unmet need, expanding its geographic footprint and market access in a new region and potentially driving incremental sales while reinforcing its commercial position supported by KKR and Impilo.

Analysis

Immedica announced on December 10, 2025 that Loargys (pegzilarginase) received marketing authorization in Oman for treatment of arginase 1 deficiency (ARG1-D) in patients aged 2 years and older, marking the company’s first approval in the MENA region and extending prior EU and UK authorizations. Loargys is described as the first and only disease‑modifying therapy for ARG1‑D and has been shown to rapidly and sustainably lower plasma arginine and its toxic metabolites with associated clinical improvements, addressing a disorder that causes spasticity, seizures, developmental delay and elevated early mortality risk.

The approval materially advances Immedica’s geographic footprint into a region with high unmet need and leverages the company’s stated commercial, regulatory and distribution capabilities across more than 50 countries; Immedica is backed by KKR and Impilo, which may support regional roll‑out. This milestone is strategically important as a precedent for additional MENA market entries and for converting a clinically differentiated asset into incremental sales in niche patient populations.

Key near‑term risks and monitoring points include the inherently small ARG1‑D patient population, the outcome of reimbursement and market‑access negotiations in Oman and other MENA countries, and the need for real‑world safety and uptake data and active pharmacovigilance to sustain adoption and payer support.

Key Decisions for Investors

• Monitor initial uptake and reimbursement decisions in Oman over the next 6–12 months as the primary read‑through for regional demand
• Maintain a cautiously constructive stance on Immedica’s commercial prospects if early sales and access metrics are positive, but limit position size given the rare‑disease patient base and uncertain pricing dynamics
• Watch for additional MENA regulatory approvals and published real‑world effectiveness or safety data as material catalysts that would justify upgrading revenue and valuation assumptions
• If exposure is via backers such as KKR, monitor reported commercial traction and any corporate communications from Immedica before making allocation changes